A sample of the COVID-19 inactivated vaccine is seen at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. (PHOTO / Xinhua)
BEIJING - Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central China's Henan province.
This is the CNBG's third COVID-19 vaccine candidate approved for human trials
Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9.
This is the CNBG's third COVID-19 vaccine candidate approved for human trials.
Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement.
Zhang Yuntao, vice president of the CNBG, said the recombinant vaccine candidate has been genetically engineered. Unlike the company's inactivated COVID-19 vaccines, the new one does not need a high-grade biosafety laboratory for manufacture, and it can quickly achieve large-scale production.
"It is designed for people aged three and above," Zhang said.
Whether the gene recombinant vaccine should be administered in three doses will be determined by the results of clinical trials, Zhang added.
Copyright 1995 - 2023. All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily. Without written authorization from China Daily, such content shall not be republished or used in any form.
HONG KONG NEWS